This week, we reflect on International Open Access Week 2024 and feature resources to help you understand and adopt OA. We share our analysis of medical research OA publication trends and highlight our innovative sing-along summary of this analysis. We signpost four Open Pharma videos that explore the basics of OA publishing, ask why we’re still debating OA, outline how to achieve more OA and consider how to ensure that OA publishing is equitable. We revisit our ISMPP University webinar on CC licences and equip you with the data you need to rebut concerns about OA publishing. Finally, we encourage you to make your commitment to OA public by endorsing the Open Pharma position statement on OA.
To read:
Benchmarking OA publications rates via bioRxiv | 30-minute read
We’re delighted to announce the release of our preprint titled Benchmarking open access publication rates for the pharmaceutical industry and research-intensive academic institutions. This study analyses open access (OA) publication trends for biomedical and health sciences research using data from the Open Pharma OA dashboard. Don’t have time to read the preprint? To celebrate International Open Access Week, we’ve used artificial intelligence to turn it into a plain language song! Let us know what you think of this innovation on our LinkedIn page.
To watch:
OA 101 via Open Pharma | 1-hour watch
Do you want to know more about what OA means in the context of medical research publications? In this video, Tim Koder (Business Director, Nexus at Oxford PharmaGenesis), Amber Tear (Principal Medial Writer at Oxford PharmaGenesis) and Joana Osório (Communications Team Leader at Oxford PharmaGenesis and Project Lead of Open Pharma) explore the different types of OA, present early data from our OA dashboard and outline the benefits of publishing OA.
Why are we still debating OA? via Open Pharma | 15-minute watch
In November 2023, Open Pharma hosted a summit that explored the landscape of open science through provocative presentations from external opinion leaders. You can still watch highlights from the summit on our YouTube channel, including Why are we still debating OA to academic research? with Durhane Wong-Rieger (President and CEO of the Canadian Organization for Rare Disorders), Roads towards more OA with Johan Rooryck (Executive Director of cOAlition S) and Equity in OA: views from the Open Access Scholarly Publishing Association (OASPA) with Malavika Legge (Open Access Program Manager at OASPA).
Demystifying CC licences via ISMPP | 1-hour watch
Navigating Creative Commons (CC) licence selection can be confusing, and getting it wrong can have long-term administrative and financial consequences. At this International Society for Medical Publication Professionals (ISMPP) University webinar, Sam Cavana (Head of Publishing Solutions at Taylor & Francis), Slávka Baróniková (Senior Director at Alfasigma), Sonia Schweers (Director, Medical Policy Governance at Bristol Myers Squibb), Valérie Philippon (Global Head, Scientific Communications, Medical Information & Medical Learning at UCB) and Sophie Nobes (Senior Medical Writer at Oxford PharmaGenesis) explored CC licence selection in the context of medical research publications and offered practical tips to help you navigate this process. If you are an ISMPP member, you can watch a recording of the session and download a copy of the presentation here. Alternatively, anyone can read the original article that led to this webinar in The MAP.
To engage with:
Open Pharma OA objection handler via Open Pharma
Are you feeling inspired to discuss OA with your colleagues and co-authors but unsure about how to respond to their concerns or questions? The Open Pharma OA objection handler has you covered! This interactive resource includes data-supported responses to common objections about OA, guidance on selecting appropriate CC licences and tips on how to identify high-quality OA journals.
Make your commitment to OA public via Open Pharma
International OA Week might be coming to a close, but our commitment to OA continues! Make your passion for OA public by endorsing the Open Pharma position statement. The statement outlines our immediate goal to secure authors of industry-funded research publications the same right to publish OA as those receiving funding from other sources and our long-term commitment to the sustainable use of CC Attribution (BY) licences
Enjoy our content? Read last week’s digest and check out our latest guest blog!
Don’t forget to follow us on Twitter/X and LinkedIn for regular updates!
